The termination of the Equity Distribution Agreement with Maxim Group could signal a strategic shift for Applied DNA Sciences in managing its equity. This may have a neutral short-term impact on the stock price as the market digests the news and awaits further details on the company's future equity distribution plans. The relevance is high as it directly affects the company's financial strategy, but the importance is moderate until more information is provided on the implications of this termination.